Otsuka (OTCMKTS:OTSKY) Sees Large Volume Increase – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw strong trading volume on Wednesday . 80,392 shares were traded during trading, an increase of 118% from the previous session’s volume of 36,937 shares.The stock last traded at $36.15 and had previously closed at $34.92.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OTSKY. The Goldman Sachs Group downgraded shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. UBS Group raised shares of Otsuka to a “hold” rating in a research note on Tuesday, January 27th. Finally, Morgan Stanley raised shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Otsuka Price Performance

The company’s 50 day moving average price is $34.52 and its 200-day moving average price is $31.35. The stock has a market cap of $38.91 billion and a P/E ratio of 15.28. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, sell-side analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.86 earnings per share for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.